The U.S. Department of Energy’s National Nuclear Security Administration (NNSA) has awarded Shine Technologies $32 million to support production of molybdenum-99 (Mo-99).
The funds will aid in the ongoing construction of Chrysalis, Shine’s large-scale, medical isotope facility in Janesville, Wisconsin. Upon its completion, Chrysalis will provide a sustainable, reliable source of Mo-99 for the U.S. and satisfy more than one-third of the world’s demand, the company said.
The funding was added to NNSA’s existing cooperative agreement with Shine as part of the agency’s efforts to help establish a reliable, U.S.-produced supply of Mo-99, the most commonly used medical isotope, without the use of highly enriched uranium, the company noted.
Commercial production of Mo-99 is expected in early 2027, Shine said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
